Cell-permeable Tat-NBD peptide attenuates rat pancreatitis and acinus cell inflammation response

Figure 3 Effects different doses of Tat-NBD (WT) in IL-1β mRNA expression of AR42J by RT-PCR. A: Images of agarose gel electrophoresis; B: Tat-NBD (WT) peptide decreased IL-1β mRNA expression in a dose-dependent manner and its peak role appeared at a dose of 100 mg/L. Control: Cells were incubated with buffer control (n = 3); 1: Control; 2: LPS; 3: 0.1 mg/L Tat-NBD (WT); 4: 1 mg/L Tat-NBD (WT); 5: 10 mg/L Tat-NBD (WT); 6: 100 mg/L Tat-NBD (WT); M: Marker. LPS: Cells stimulated by LPS for 2 h (n = 3). 0.1: Pretreatment with 0.1 mg/L of Tat-NBD (WT) (n = 3); 1: Pretreatment with 1 mg/L of Tat-NBD (WT) (n = 3); 10: Pretreatment with 10 mg/L of Tat-NBD (WT) (n = 3); 100: Pretreatment with 100 mg/L of Tat-NBD (WT) (n = 3). ^bP < 0.01 vs LPS group. ^dP < 0.01 vs LPS group.